{"id":"W4391887693","doi":"10.1016/j.jinf.2024.106120","title":"Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial","year":2024,"lang":"en","type":"letter","venue":"Journal of Infection","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"Cilag; Fonds Erasme; Gilead Sciences; Conseil Régional, Île-de-France; Celgene; AstraZeneca; European Commission; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Coronavirus disease 2019 (COVID-19); Placebo; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Double blind; 2019-20 coronavirus outbreak; Randomized controlled trial; Betacoronavirus; Internal medicine; Virology; Alternative medicine; Pathology; Disease; Outbreak","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004018367,0.0007012309,0.002650684,0.0002610054,0.0003618503,0.00142144,0.0009652297,0.003567813,0.004268524],"category_scores_gemma":[0.006434565,0.0003734267,0.002621275,0.0003621311,0.0006140996,0.001266568,0.0002734955,0.004391483,0.0005497419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000542023,"about_ca_system_score_gemma":0.0009828021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004524739,"about_ca_topic_score_gemma":0.001207556,"domain_scores_codex":[0.9989464,0.0006070685,0.0001188722,0.0001072455,0.0001223297,0.0000981759],"domain_scores_gemma":[0.9970901,0.00156253,0.00070006,0.0000730204,0.0002795821,0.0002945977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.78932,0.003540139,0.00293068,0.01856769,0.01203117,0.0003285575,0.0001916291,0.0004336834,0.002937562,0.0009221262,0.06507546,0.1037214],"study_design_scores_gemma":[0.9193857,0.02942048,0.006475654,0.002568091,0.009655568,0.0002226266,0.00009424312,0.001369068,0.001004647,0.0007835033,0.02894726,0.00007304085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.373744,0.4261521,0.001937119,0.1274659,0.0498141,0.005223115,0.004835482,0.0005389908,0.01028926],"genre_scores_gemma":[0.7336993,0.1210847,0.003811449,0.0898779,0.03522743,0.004656676,0.002388073,0.0001498759,0.009104608],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004268524,"threshold_uncertainty_score":0.02125138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04652751616575388,"score_gpt":0.3827364188631838,"score_spread":0.3362089026974299,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}